mei pharma  pioneering new therapies for cancer skip to main content search form search print email pioneering new therapies for cancer   about us we are a san diegobased oncology company focused on the clinical development of novel therapies for cancer our pipeline of drug candidates includes pracinostat an oral hdac inhibitor in latestage clinical development for the treatment of aml and mds me a highly selective pik delta inhibitor being developed for bcell malignancies and me a novel mitochondrial inhibitorread about us latest news correlation between gene mutations and clinical response in phase ii study of pracinostat and azacitidine in amlpress release  asco  eha first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in mdspress release prespecified response rate exceeded in doseescalation study of me in cll and follicular lymphomapress release third quarter fiscal year  resultspress release  q presentation at needham healthcare conferencewebcast  slides   highlights view  annual review mei pharma appoints new cfo mei pharma rides wave of interest in aml search form search print email home about us programs newsroom investors careers contact mei pharma  investors skip to main content search form search print email investors mei pharma nasdaq meip is a san diegobased oncology drug development company with a pipeline of three clinicalstage drug candidates and a management team with proven oncology drug development experience as of march   we had  million in cash cash equivalents and shortterm investments with no outstanding debt our common stock is traded on the nasdaq capital market under the symbol meip latest press releases news alerts jun  helsinn group and mei pharma announce first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in myelodysplastic syndrome jun  helsinn group and mei pharma report correlation between mutations in dna methylation pathway and clinical response in phase ii study of pracinostat and azacitidine in acute myeloid leukemia may  mei pharma announces prespecified response rate exceeded in doseescalation study of me in chronic lymphocytic leukemia and follicular lymphoma may  helsinn group and mei pharma announce upcoming presentations of gene mutation and clinical response data from phase ii study of pracinostat and azacitidine in acute myeloid leukemia corporate presentation needham healthcare conference april   kb   stock quotenasdaqmeip dymomoyryrcontact pete de spain vice president investor relations mei pharma inc  investormeipharmacom search form search print email home about us programs newsroom investors stock information events  webcasts sec filings annual report analyst coverage corporate governance news alerts contact ir financial reporting careers contact about us  mei pharma skip to main content search form search print email about us mei pharma is a san diegobased oncology company focused on the clinical development of novel therapies for cancer our portfolio of drug candidates includes pracinostat an oral hdac inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia aml and myelodysplastic syndrome mds our clinical development pipeline also includes me a highly selective oral pik delta inhibitor and me a novel mitochondrial inhibitor in august  we announced that the us food  drug administration granted breakthrough therapy designation for pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed aml who are unfit for intensive chemotherapy later that month we entered into an exclusive licensing development and commercialization agreement with helsinn healthcare sa a swiss pharmaceutical company for pracinostat in aml and other potential indications including mds me is a potent and selective oral inhibitor of pik delta a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells results from a firstinhuman single ascending dose clinical study suggest that me has the potential for an improved therapeutic window compared to other pik delta inhibitors with a halflife that supports oncedaily dosing a phase ib doseescalation study of me in patients with relapsedrefractory chronic lymphocytic leukemia cll or follicular lymphoma opened for enrollment in september  me is our isoflavonederived mitochondrial inhibitor drug candidate results from a phase i clinical study of me in patients with refractory solid tumors showed evidence of clinical activity including a confirmed partial response in a heavily pretreated patient with small cell lung cancer who remained on study for two years an investigatorsponsored study of me in combination with the vegf inhibitor bevacizumab marketed as avastin® in hernegative breast cancer opened for enrollment in august  mei pharma is listed on the nasdaq capital market nasdaq meip   management our management team comes with a deep understanding of oncology drug development including experience with the worlds leading oncology drugsread more directors our board of directors combines decades of oncology drug development business and wall street experience to add valuable perspective to the companyread more search form search print email home about usmanagement directors programs newsroom investors careers contact our programs  mei pharma skip to main content search form search our programs epigenetics program drug candidate pracinostat hdac inhibitor indication  combinationacute myeloid leukemianewly diagnosed unfit for intensive chemotherapyazacitidine vidaza®preclinicalphase iphase iiphase iii indication  combinationmyelodysplastic syndromehigh  very high riskazacitidine vidaza®preclinicalphase iphase iiphase iii indication  combinationmyelofibrosisfront line  relapsedrefractoryruxolitinib jakafi®preclinicalphase iphase iiphase iii  signaling program drug candidate me pik delta inhibitor indication  combinationcll  follicular lymphomarelapsedrefractorysingle agentpreclinicalphase iphase iiphase iii  cancer metabolism program drug candidate me mitochondrial inhibitor indication  combinationhernegative breasttreatmentnaïve early stagebevacizumab avastinpreclinicalphase iphase iiphase iii  search form search home about us programspracinostat me me clinical trials publications newsroom investors careers contact mei pharma  newsroom skip to main content search form search print email newsroom get news alerts by email archives search                jun  helsinn group and mei pharma announce first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in myelodysplastic syndrometwostage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk mds jun  helsinn group and mei pharma report correlation between mutations in dna methylation pathway and clinical response in phase ii study of pracinostat and azacitidine in acute myeloid leukemia may  mei pharma announces prespecified response rate exceeded in doseescalation study of me in chronic lymphocytic leukemia and follicular lymphoma may  helsinn group and mei pharma announce upcoming presentations of gene mutation and clinical response data from phase ii study of pracinostat and azacitidine in acute myeloid leukemiadata to be presented at asco and eha in june abstracts now available online may  mei pharma reports third quarter fiscal year  results apr  mei pharma announces appointment of brian drazba as chief financial officer mar  mei pharma to present at needham healthcare conferencelive webcast from new york on april th mar  mei pharma to present at oppenheimer healthcare conferencelive webcast from new york on march st feb  mei pharma reports second quarter fiscal year  resultscompany begins calendar year with  million in cash dec  helsinn group and mei pharma report prolongation of survival results from phase  clinical study of pracinostat and azacitidine in acute myeloid leukemiaphase  study results presented at american society of hematology annual meeting on saturday december   nov  mei pharma to host annual meeting of stockholderslive webcast from san diego on december st nov  mei pharma reports first quarter fiscal year  resultsquarter highlighted by breakthrough therapy designation and global strategic partnership for pracinostat nov  mei pharma to present at stifel healthcare conferencelive webcast from new york on november th nov  helsinn group and mei pharma announce longterm survival and response data from phase ii clinical study of pracinostat in acute myeloid leukemia accepted for oral presentation at upcoming american society of hematology annual meetingdata to be presented on december   abstract now available online sep  mei pharma reports fiscal year  resultscompany now well positioned with fully funded phase iiiready asset emerging pipeline and strong cash balance   search form search print email home about us programs newsroom investors careers contact terms  conditions  mei pharma skip to main content search form search print email terms  conditions please read our terms  conditions and privacy policy carefully before using the mei pharma inc website by using this website you agree to follow these terms  conditions and the privacy policy in the case of any violation of these terms  conditions mei pharma reserves the right to seek all remedies available by law and in equity for such violations mei pharma also reserves the right to change these terms from time to time at its sole discretion for that reason we encourage you to review this statement periodically by using our website you agree to the terms  conditions in effect at that time your use of this website constitutes acceptance of these terms  conditions if you do not agree please exit from this website immediately use of website the mei pharma website may contain other proprietary notices and copyright information the terms of which must be observed and followed information on this site may contain technical inaccuracies or typographical errors information may be changed or updated without notice links the mei pharma website may contain links to other websites mei pharma is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement by mei pharma of the site or any association with its operators if you use these links you are leaving this website mei pharma has not reviewed all of these thirdparty sites and does not have control over and is in no manner responsible or liable for the availability and content of these sites mei pharma makes no representations whatsoever about any other site you may access through mei pharma and disclaims all liability with regard to your access to such linked websites if you access any of the thirdparty sites linked to this website you do so at your own risk unless otherwise set forth in a written agreement between you and mei pharma you must adhere to mei pharmas’ linking policy as follows i any link to the mei pharma website must be a text only link clearly marked mei pharma website ii the appearance position and other aspects of the link may not be such as to damage or dilute the goodwill associated with mei pharma’ name and trademarks and iii the link must point to the following url listed below wwwmeipharmacom and not to other pages within the website iv the appearance position and other attributes of the link may not create the false appearance that your organization or entity is sponsored by affiliated with or associated with mei pharma and v mei pharma reserves the right to revoke its consent to the link at any time and in its sole discretion disclaimer warranty you assume all responsibility and risk for the use of this web site and the internet generally this web site is provided by mei pharma on an as is basis mei pharma makes no representations or warranties of any kind express or implied as to the operation of the site or the information content materials or products included on this web site to the full extent permissible by applicable law mei pharma disclaims all warranties express or implied including but not limited to implied warranties of merchantability and fitness for a particular purpose noninfringement of intellectual property rights or other proprietary rights and freedom from errors viruses bugs or other harmful components mei pharma will not be liable for any damages or any kind arising from the use of this web site including but not limited to direct indirect special incidental punitive consequential damages or damages resulting from loss of use data or profits or business interruption arising out of or in any way connected with the use of the web site any delays on the web site or the inability to use the web site any portion thereof or any hyperlinked web site whether based on contract tort negligence strict liability or otherwise even if mei pharma has been advised of the possibility of such damages forwardlooking statements except for historical information this website may contain forwardlooking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made these forwardlooking statements represent the judgment of mei pharma as of the date of this website development andor update and mei pharma disclaims any intent or obligation to update these forwardlooking statements general terms if any provision of these terms  conditions is found to be invalid by any court having competent jurisdiction the invalidity of such provision shall not affect the validity of the remaining provisions of these terms  conditions which shall remain in full force and effect no waiver of any of these terms  conditions shall be deemed a further or continuing waiver of such term or condition or any other term or condition if you violate these terms  conditions in a way that causes harm to others you agree to hold mei pharma harmless against any liability for that harm location  governing law by using this website you agree that the only proper jurisdiction and venue for any dispute with mei pharma or in any way relating to your use of this website is in the state and federal courts in the state of california usa these terms  conditions are governed by the internal substantive laws of the state of california without respect to its conflict of laws principles and the federal laws of the united states search form search print email home about us programs newsroom investors careers contact management  mei pharma skip to main content search form search print email management daniel gold phd president  chief executive officer dr gold was appointed president  chief executive officer in april  he joined the company with approximately  years of drug discovery and development experience most recently as president and chief executive officer of prospect therapeutics a midstage oncology company prior to his tenure at prospect dr gold was founder and chief scientific officer of favrille where he was an integral member of a team that advanced the companys lead oncology candidate through a pivotal phase iii clinical trial he currently serves on the board of trustees of the hope funds for cancer research dr golds academic qualifications include postdoctoral fellowships at the danafarber cancer institute at the harvard school of medicine and the massachusetts institute of technology center for cancer research he holds a phd in pathologyimmunology from tufts university boston and a bachelors degree in biology from the university of california los angeles  robert mass md chief medical officer dr mass has more than  years of experience as a medical oncologist in both clinical practice and clinical drug development he held a number of leadership positions at genentech from  to  most recently as head of medical affairs biooncology a position created to strategically integrate and optimize all of the nonsponsored clinical programs within the company’s oncology portfolio he also served on the executive development review committee at genentech which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio previously he served as clinical science leader for herceptin® from  to  tarceva® from  to  and avastin® currently the leading oncology therapeutic worldwide from  to  prior to joining genentech he practiced hematology and medical oncology from  to  dr mass earned his bachelor’s degree in economics from tufts university and his medical degree from oregon health  science university he is certified by the american board of internal medicine in both internal medicine and medical oncology  brian drazba chief financial officer mr drazba joined as chief financial officer in april  with more than  years of financial management experience in the healthcare industry previously he served as vice president of finance and chief financial officer of heron therapeutics a commercialstage biotechnology company from october  to march  from  to  he was vice president of finance and chief accounting officer for ista pharmaceuticals a commercialstage pharmaceutical company ista pharmaceuticals was acquired by bausch  lomb in june  from  to  mr drazba held various positions of increasing responsibility within insight health corp most recently as senior vice president and chief accounting officer he began his career at arthur andersen  co a public accounting firm mr drazba is a licensed certified public accountant in california and received a ba degree in accounting from the university of san diego david urso jd senior vice president corporate development  general counsel mr urso joined mei pharma in march  with more than two decades of experience in the life science industry most recently as chief operating officer and general counsel at tioga pharmaceuticals a privately held drug development company he cofounded in  previously he was a principal at forward ventures where he was responsible for identifying and developing life science venture capital investments prior to joining forward ventures in  mr urso was director of corporate development and legal affairs at dna sciences previously he worked as an attorney in the corporate securities and licensing groups at wilson sonsini goodrich  rosati llp and cooley godward llp after beginning his career as a bench scientist at smithkline beecham and the university of pennsylvania medical school mr urso received a jd from harvard law school and a bachelors degree in molecular biology and philosophy from reed college karen potts phd senior vice president regulatory affairs dr potts joined as senior vice president regulatory affairs in october  her career spans both the biotechnology and pharmaceutical industries where she has led global regulatory teams to successfully facilitate the development approval and life cycle management of therapeutic drugs and biologics most recently dr potts served as senior vice president of regulatory affairs at trius therapeutics until its acquisition by cubist pharmaceuticals in september  previously she served as senior director regulatory policy at allergan where she was responsible for global regulatory strategy and policy prior to that dr potts held various strategic positions at isis pharmaceuticals pfizer and agouron pharmaceuticals she began her career as a postdoctoral fellow at the center for disease control division of hivaids and subsequently became a senior research scientist in infectious disease at searle dr potts received a bachelors degree in biology from smith college and a phd in microbiology and immunology from emory university   richard ghalie md senior vice president clinical development dr ghalie was appointed as senior vice president clinical development in march  he is a hematologist and oncologist with more than  years of drug development experience at public and private companies dr ghalie has held several executive positions in the pharmaceutical industry including serving as chief medical officer at denovo biopharma hemaquest pharmaceuticals novalar pharmaceuticals and favrille and previously as vice president at ligand pharmaceuticals and neorx he was the medical lead of teams that successfully filed ndas and maas resulting in the approval of four new indications previously he served as medical director of the bone marrow transplant center of rush university medical center dr ghalie holds a medical degree from the french school of medicine in lebanon a ms from the university paris xi and a mba from the university of washington in seattle he has authored or coauthored more than  manuscripts book chapters and scientific publications ofir moreno phd vice president research  development dr moreno joined mei pharma as vice president preclinical research in september  and was appointed vice president research  development in july  during the span he was instrumental in advancing two of the companys preclinical isoflavonebased drug candidates through investigational new drugenabling studies and into clinical trials dr moreno has nearly  years of experience in the pharmaceutical industry including positions of increasing responsibility at merck amgen and corvas international acquired by dendreon from august  to november  he served as senior director of chemistry at dendreon where he was responsible for designing and implementing the companys smallmolecule research and development platform with a strategic emphasis on outsourcing dr moreno earned his bachelors degree in biology and chemistry from cornell university and his phd in organic chemistry from harvard university  pete de spain vice president investor relations  corporate communications mr de spain joined the company in july  with more than  years of investor relations and corporate communications experience primarily for publicly traded biotechnology companies most recently he served as sr director investor relations  corporate communications at prometheus laboratories a pharmaceutical and diagnostics company before its acquisition by nestlé health science prior to that he was director investor relations  corporate communications at favrille a cancer immunotherapy company previously he served in similar roles of increasing responsibility at anadys pharmaceuticals acquired by roche sequenom acquired by labcorp and sunrise medical he is immediate past president of the san diego chapter of the national investor relations institute niri mr de spain received his bachelors degree in communication with a public relations emphasis from san diego state university search form search print email home about usmanagement directors programs newsroom investors careers contact market report mei pharma inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing mei pharma inc  product pipeline review   nov    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs mei pharma inc  product pipeline review   provides an overview of the mei pharma incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of mei pharma incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the mei pharma incs pipeline productsreasons to buyevaluate mei pharma incs strategic position with total access to detailed information on its product pipelineassess the growth potential of mei pharma inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the mei pharma incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresmei pharma inc snapshotmei pharma inc overviewkey informationkey factsmei pharma inc  research and development overviewkey therapeutic areasmei pharma inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapymei pharma inc  pipeline products glancemei pharma inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesmei pharma inc  early stage pipeline productspreclinical productscombination treatment modalitiesmei pharma inc  drug profilespracinostatproduct descriptionmechanism of actionrd progressmeproduct descriptionmechanism of actionrd progresspwtproduct descriptionmechanism of actionrd progressnvproduct descriptionmechanism of actionrd progressmei pharma inc  pipeline analysismei pharma inc  pipeline products by targetmei pharma inc  pipeline products by route of administrationmei pharma inc  pipeline products by molecule typemei pharma inc  pipeline products by mechanism of actionmei pharma inc  recent pipeline updatesmei pharma inc  dormant projectsmei pharma inc  locations and subsidiarieshead officeappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesmei pharma inc key informationmei pharma inc key factsmei pharma inc  pipeline by indication mei pharma inc  pipeline by stage of development mei pharma inc  monotherapy products in pipeline mei pharma inc  phase ii mei pharma inc  phase i mei pharma inc  preclinical mei pharma inc  pipeline by target mei pharma inc  pipeline by route of administration mei pharma inc  pipeline by molecule type mei pharma inc  pipeline products by mechanism of action mei pharma inc  recent pipeline updates mei pharma inc  dormant developmental projectslist of figuresmei pharma inc  pipeline by top  indication mei pharma inc  pipeline by stage of development mei pharma inc  monotherapy products in pipeline mei pharma inc  pipeline by top  target mei pharma inc  pipeline by top  route of administration mei pharma inc  pipeline by top  molecule type mei pharma inc  pipeline products by top  mechanism of action  companies mentioned in this reportmei pharma inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc mei pharma inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals mei pharma inc  product pipeline review   published nov  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample mei pharma inc  product pipeline review   summary global markets direct’s ‘mei pharma inc  product pipeline review  ’ provides an overview of the mei pharma inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of mei pharma inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the mei pharma inc’s pipeline products reasons to buy  evaluate mei pharma inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of mei pharma inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the mei pharma inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  mei pharma inc snapshot  mei pharma inc overview  key information  key facts  mei pharma inc  research and development overview  key therapeutic areas  mei pharma inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  mei pharma inc  pipeline products glance  mei pharma inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  mei pharma inc  early stage pipeline products  preclinical productscombination treatment modalities  mei pharma inc  drug profiles  pracinostat  product description  mechanism of action  rd progress  me  product description  mechanism of action  rd progress  pwt  product description  mechanism of action  rd progress  nv  product description  mechanism of action  rd progress  mei pharma inc  pipeline analysis  mei pharma inc  pipeline products by target  mei pharma inc  pipeline products by route of administration  mei pharma inc  pipeline products by molecule type  mei pharma inc  pipeline products by mechanism of action  mei pharma inc  recent pipeline updates  mei pharma inc  dormant projects  mei pharma inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables mei pharma inc key information  mei pharma inc key facts  mei pharma inc  pipeline by indication   mei pharma inc  pipeline by stage of development   mei pharma inc  monotherapy products in pipeline   mei pharma inc  phase ii   mei pharma inc  phase i   mei pharma inc  preclinical   mei pharma inc  pipeline by target   mei pharma inc  pipeline by route of administration   mei pharma inc  pipeline by molecule type   mei pharma inc  pipeline products by mechanism of action   mei pharma inc  recent pipeline updates   mei pharma inc  dormant developmental projects  list of figures mei pharma inc  pipeline by top  indication   mei pharma inc  pipeline by stage of development   mei pharma inc  monotherapy products in pipeline   mei pharma inc  pipeline by top  target   mei pharma inc  pipeline by top  route of administration   mei pharma inc  pipeline by top  molecule type   mei pharma inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors jun  gbi research  pages    code  mrs   global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors summary in  there were  million people living with any type of cancer within five years of diagnosis these are generally incurable once they progress to the stage where they are unresectable chemotherapy compounds are a mainstay treatment for cancers of all types at various disease stages in a typical course of therapy for cancer multiple chemothera read more interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  summary interleukin  receptor subunit alpha cdw or cd or ilr  interleukin receptor is a protein found on the surface of cells it is a receptor for interleukin it acts as a receptor for thymic stromal lymphopoietin tslp it plays an important role in tcell acute lymphoblastic leukemia multiple sclerosis rheumatoid arthritis and juvenile idiopathic arthritis interleukin  recep read more  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  jul  global markets direct  pages    code  mrs    kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  summary  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa pipeline target constitutes close to  molecules out of which approximately  molecules are devel read more survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  jul  global markets direct  pages    code  mrs   survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  summary according to the recently published report survival motor neuron protein  pipeline review h  survival motor neuron protein component of gems  or gemin  or smn or smn pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies and remaining by the universitiesinstitutes survival motor neuron protein  read more rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  jul  global markets direct  pages    code  mrs   rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  summary rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   rhoassociated protein kinase  rock is a protein serinethreonine kinase it is a key regulator of actin cytoskeleton and read more serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  jul  global markets direct  pages    code  mrs   serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  summary serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies the latest report serinethreonine protein kinase a raf  pipeline review h  outlays comprehensive information on the serin read more map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  summary according to the recently published report map kinase interacting serinethreonine protein kinase   pipeline review h  map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec  pipeline target constitutes close to  molecules out of which approximately  molecu read more interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  summary interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   interleukin receptorassociated kinase  irak is a protein kinase involved in signaling innate immune responses from tolllike receptors mutations in irak result in irak deficiency and recurrent invasive pneumococcal disease it phosphoryla read more mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  summary mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by read more protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  jul  global markets direct  pages    code  mrs   protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  summary according to the recently published report protein glutamine gamma glutamyltransferase   pipeline review h  protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports mei pharma  investors skip to main content search form search print email investors mei pharma nasdaq meip is a san diegobased oncology drug development company with a pipeline of three clinicalstage drug candidates and a management team with proven oncology drug development experience as of march   we had  million in cash cash equivalents and shortterm investments with no outstanding debt our common stock is traded on the nasdaq capital market under the symbol meip latest press releases news alerts jun  helsinn group and mei pharma announce first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in myelodysplastic syndrome jun  helsinn group and mei pharma report correlation between mutations in dna methylation pathway and clinical response in phase ii study of pracinostat and azacitidine in acute myeloid leukemia may  mei pharma announces prespecified response rate exceeded in doseescalation study of me in chronic lymphocytic leukemia and follicular lymphoma may  helsinn group and mei pharma announce upcoming presentations of gene mutation and clinical response data from phase ii study of pracinostat and azacitidine in acute myeloid leukemia corporate presentation needham healthcare conference april   kb   stock quotenasdaqmeip dymomoyryrcontact pete de spain vice president investor relations mei pharma inc  investormeipharmacom search form search print email home about us programs newsroom investors stock information events  webcasts sec filings annual report analyst coverage corporate governance news alerts contact ir financial reporting careers contact mei pharma inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports mei pharma inc  product pipeline review   mei pharma inc  product pipeline review   wgr  june  global  pages global markets direct description table of content sample report enquiry before buy related reports mei pharma inc  product pipeline review  summaryglobal markets direct’s ‘mei pharma inc  product pipeline review  ’ provides an overview of the mei pharma inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of mei pharma inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the mei pharma inc’s pipeline productsreasons to buy evaluate mei pharma inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of mei pharma inc in its therapy areas of focus identify new drug targets and therapeutic classes in the mei pharma inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures mei pharma inc snapshot mei pharma inc overview key information key facts mei pharma inc  research and development overview key therapeutic areas mei pharma inc  pipeline review pipeline products by stage of development pipeline products  monotherapy mei pharma inc  pipeline products glance mei pharma inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities mei pharma inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities mei pharma inc  drug profiles pracinostat product description mechanism of action rd progress me product description mechanism of action rd progress me product description mechanism of action rd progress nv product description mechanism of action rd progress pwt product description mechanism of action rd progress sb product description mechanism of action rd progress mei pharma inc  pipeline analysis mei pharma inc  pipeline products by target mei pharma inc  pipeline products by route of administration mei pharma inc  pipeline products by molecule type mei pharma inc  pipeline products by mechanism of action mei pharma inc  recent pipeline updates mei pharma inc  dormant projects mei pharma inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesmei pharma inc key information mei pharma inc key facts mei pharma inc  pipeline by indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  phase ii  mei pharma inc  phase i  mei pharma inc  preclinical  mei pharma inc  discovery  mei pharma inc  pipeline by target  mei pharma inc  pipeline by route of administration  mei pharma inc  pipeline by molecule type  mei pharma inc  pipeline products by mechanism of action  mei pharma inc  recent pipeline updates  mei pharma inc  dormant developmental projects list of figuresmei pharma inc  pipeline by top  indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  pipeline by top  target  mei pharma inc  pipeline by top  route of administration  mei pharma inc  pipeline by top  molecule type  mei pharma inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send mei pharma inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies market research report mei pharma inc  product pipeline review   published by global markets direct product code  published november   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license mei pharma inc  product pipeline review   published november   content info  pages description summary global markets directs mei pharma inc  product pipeline review   provides an overview of the mei pharma incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of mei pharma incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the mei pharma incs pipeline products reasons to buy evaluate mei pharma incs strategic position with total access to detailed information on its product pipeline assess the growth potential of mei pharma inc in its therapy areas of focus identify new drug targets and therapeutic classes in the mei pharma incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdb table of contents table of contents list of tables list of figures mei pharma inc snapshot mei pharma inc overview key information key facts mei pharma inc  research and development overview key therapeutic areas mei pharma inc  pipeline review pipeline products by stage of development pipeline products  monotherapy mei pharma inc  pipeline products glance mei pharma inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities mei pharma inc  early stage pipeline products preclinical productscombination treatment modalities mei pharma inc  drug profiles pracinostat product description mechanism of action rd progress me product description mechanism of action rd progress pwt product description mechanism of action rd progress nv product description mechanism of action rd progress mei pharma inc  pipeline analysis mei pharma inc  pipeline products by target mei pharma inc  pipeline products by route of administration mei pharma inc  pipeline products by molecule type mei pharma inc  pipeline products by mechanism of action mei pharma inc  recent pipeline updates mei pharma inc  dormant projects mei pharma inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables mei pharma inc key information mei pharma inc key facts mei pharma inc  pipeline by indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  phase ii  mei pharma inc  phase i  mei pharma inc  preclinical  mei pharma inc  pipeline by target  mei pharma inc  pipeline by route of administration  mei pharma inc  pipeline by molecule type  mei pharma inc  pipeline products by mechanism of action  mei pharma inc  recent pipeline updates  mei pharma inc  dormant developmental projects list of figures mei pharma inc  pipeline by top  indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  pipeline by top  target  mei pharma inc  pipeline by top  route of administration  mei pharma inc  pipeline by top  molecule type  mei pharma inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved mei pharma inc  product pipeline review      about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing you are here home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure thank you very much for the quick report delivery and response for all my requests and inquiries you and your team worked very efficiently to help me get the report i was looking for the online purchase process also worked flawlessly and left a very professional and reliable impression to me using your services for the first time – and certainly not the last thanks read more dr arno avela application marketing manager borealis polymers oy mei pharma inc  product pipeline review   id  company profile november   pages global markets direct description table of contents samples formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend mei pharma inc  product pipeline review  summarythe report ‘mei pharma inc  product pipeline review  ’ provides an overview of the mei pharma inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsthe report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profilesrecords featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of mei pharma inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the mei pharma inc’s pipeline productsreasons to buy evaluate mei pharma inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of mei pharma inc in its therapy areas of focus identify new drug targets and therapeutic classes in the mei pharma inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areas avoid intellectual property rights related issues show less read more note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend list of tables list of figures mei pharma inc snapshot mei pharma inc overview key information key facts mei pharma inc  research and development overview key therapeutic areas mei pharma inc  pipeline review pipeline products by stage of development pipeline products  monotherapy mei pharma inc  pipeline products glance mei pharma inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities mei pharma inc  early stage pipeline products preclinical productscombination treatment modalities mei pharma inc  drug profiles pracinostat product description mechanism of action rd progress me product description mechanism of action rd progress pwt product description mechanism of action rd progress nv product description mechanism of action rd progress mei pharma inc  pipeline analysis mei pharma inc  pipeline products by target mei pharma inc  pipeline products by route of administration mei pharma inc  pipeline products by molecule type mei pharma inc  pipeline products by mechanism of action mei pharma inc  recent pipeline updates mei pharma inc  dormant projects mei pharma inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesmei pharma inc key information mei pharma inc key facts mei pharma inc  pipeline by indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  phase ii  mei pharma inc  phase i  mei pharma inc  preclinical  mei pharma inc  pipeline by target  mei pharma inc  pipeline by route of administration  mei pharma inc  pipeline by molecule type  mei pharma inc  pipeline products by mechanism of action  mei pharma inc  recent pipeline updates  mei pharma inc  dormant developmental projects list of figuresmei pharma inc  pipeline by top  indication  mei pharma inc  pipeline by stage of development  mei pharma inc  monotherapy products in pipeline  mei pharma inc  pipeline by top  target  mei pharma inc  pipeline by top  route of administration  mei pharma inc  pipeline by top  molecule type  mei pharma inc  pipeline products by top  mechanism of action  note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products mei pharma inc  product pipeline review    company profile june  from €eurusd£gbp umn pharma inc  product pipeline review    company profile august  from €eurusd£gbp array biopharma inc  product pipeline review    company profile november  from €eurusd£gbp antares pharma inc  product pipeline review    company profile  pages may  region global from €eurusd£gbp plx pharma inc  product pipeline review    company profile may  from €eurusd£gbp beta pharma inc  product pipeline review    company profile february  from €eurusd£gbp cerulean pharma inc  product pipeline review    company profile august  from €eurusd£gbp acceleron pharma inc  product pipeline review    company profile april  from €eurusd£gbp advicenne pharma  product pipeline review    company profile august  from €eurusd£gbp signpath pharma inc  product pipeline review    company profile july  from €eurusd£gbp close mei pharma inc  product pipeline review   close ask a question required information product mei pharma inc  product pipeline review   your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change mei pharma inc  product pipeline review   sales and support     uk     us infomarketpublisherscom business  finance retail retail consumer goods food  beverage industry chemicals it  technology life sciences medical devices anesthesia  respiratory cardiovascular devices dental diabetes care diagnostic equipment drug delivery endoscopy ear nose  throat ent healthcare equipmentsupplies company reports implants neurology orthopedic ophthalmic surgical equipment wound closure other medical devices biotechnology biomarkers biomaterials biosimilars stem cell diagnostics  diseases in vitro diagnostics incontinence cancer cardiovascular diabetes hepatitis healthcare healthcare services company reports ear care eye care hospital medicated skin care therapy wound care pharmaceuticals clinical trial drug stores drugs pharmaceuticals company reports vaccines medical products veterinary services about faq my cart market reports pressreleases events about us terms  conditions customer faq market research reports life sciences pharmaceuticals mei pharma inc  product pipeline review   date november   pages  price us  license  singleuser license  us  site license  us  enterprisewide license  us  publisher global markets direct report type strategic report delivery email delivery pdf id maafden leaflet download pdf leaflet abstracts contents list of tables list of figures mei pharma inc  product pipeline review  summaryglobal markets direct’s ‘mei pharma inc  product pipeline review  ’ provides an overview of the mei pharma inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of mei pharma inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of mei pharma inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of mei pharma inc’s human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statement latest news and deals relating to the mei pharma inc’s pipeline productsreasons to buyevaluate mei pharma inc’s strategic position with total access to detailed information on its product pipelineassess the growth potential of mei pharma inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the mei pharma inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of mei pharma inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of mei pharma incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of mei pharma inc and identify potential opportunities in those areasavoid intellectual property rights related issues mei pharma inc snapshotmei pharma inc overviewkey informationkey factsmei pharma inc  research and development overviewkey therapeutic areasmei pharma inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapymei pharma inc  pipeline products glancemei pharma inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesmei pharma inc  early stage pipeline productspreclinical productscombination treatment modalitiesmei pharma inc  drug profilespracinostatproduct descriptionmechanism of actionrd progressmeproduct descriptionmechanism of actionrd progresspwtproduct descriptionmechanism of actionrd progressnvproduct descriptionmechanism of actionrd progressmei pharma inc  pipeline analysismei pharma inc  pipeline products by targetmei pharma inc  pipeline products by route of administrationmei pharma inc  pipeline products by molecule typemei pharma inc  pipeline products by mechanism of actionmei pharma inc  recent pipeline updatesmei pharma inc  dormant projectsmei pharma inc  locations and subsidiarieshead officeappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimer list of tablesmei pharma inc key informationmei pharma inc key factsmei pharma inc  pipeline by indication mei pharma inc  pipeline by stage of development mei pharma inc  monotherapy products in pipeline mei pharma inc  phase ii mei pharma inc  phase i mei pharma inc  preclinical mei pharma inc  pipeline by target mei pharma inc  pipeline by route of administration mei pharma inc  pipeline by molecule type mei pharma inc  pipeline products by mechanism of action mei pharma inc  recent pipeline updates mei pharma inc  dormant developmental projects list of figuresmei pharma inc  pipeline by top  indication mei pharma inc  pipeline by stage of development mei pharma inc  monotherapy products in pipeline mei pharma inc  pipeline by top  target mei pharma inc  pipeline by top  route of administration mei pharma inc  pipeline by top  molecule type mei pharma inc  pipeline products by top  mechanism of action  skip to top more publications raqualia pharma inc  product pipeline review   us  jul  ·  pages beech tree labs inc  product pipeline review   us  may  ·  pages ask your question mei pharma inc  product pipeline review   company name contact person phonefax email request invoice your enquiry please click on a check box below to confirm you are not a robot market reports all categories biotechnology biomarkers biomaterials biosimilars stem cell diagnostics  diseases in vitro diagnostics incontinence cancer cardiovascular diabetes hepatitis healthcare healthcare services company reports ear care eye care hospital medicated skin care therapy wound care medical devices anesthesia  respiratory cardiovascular devices dental devices diabetes care diagnostic equipment drug delivery endoscopy ear nose  throat ent devices healthcare equipmentsupplies company reports neurology orthopedic devices ophthalmic surgical equipment wound closure other medical devices medical products pharmaceuticals clinical trials drug stores drugs pharmaceuticals company reports vaccines veterinary sales and support         infomarketpublisherscom   marketpublisherscom about us our clients our publishers customer faq market reports new publications reports by regions pressreleases terms  conditions privacy policy return policy affiliate program join as publisher follow us mei pharma inc  nasdaqmeip  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street mei pharma inc meip follow  nasdaq  health care jul    pm edt prev close  day lowhigh     wk lowhigh    avg volume k exchange nasdaq shares outstanding m market cap m eps  pe ratio na div  yield na na trade with jim cramer  days free latest news helsinn group and mei pharma announce first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in myelodysplastic syndrome helsinn group and mei pharma report correlation between mutations in dna methylation pathway and clinical response in phase ii study of pracinostat and azacitidine in acute myeloid leukemia mei pharma announces prespecified response rate exceeded in doseescalation study of me in chronic lymphocytic leukemia and follicular lymphoma may    am edt helsinn group and mei pharma announce upcoming presentations of gene mutation and clinical response data from phase ii study of pracinostat and azacitidine in acute myeloid leukemia data to be presented at asco and eha in june abstracts now available online may    am edt mei pharma announces appointment of brian drazba as chief financial officer apr    am edt mei pharma to present at needham healthcare conference live webcast from new york on april th mar    am edt mei pharma to present at oppenheimer healthcare conference live webcast from new york on march st mar    am edt interesting meip call options for december th investors in mei pharma inc saw new options begin trading this week for the december th expiration one of the key data points that goes into the price an option buyer is willing to pay is the time value so with  days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration aug    am edt mei pharma meip stock soars on leukemia treatments phase  trial results mei pharma meip stock is surging in earlymorning trading on monday after the oncology company announced positive results from its leukemia treatments phase ii trial dec    am est mei pharma meip stock rises today following mondays sharp decline shares of mei pharma meip were up in late morning trading tuesday as investors swooped into the stock following its significant decline on monday mar    am edt mei pharma meip stock plummets to week low after cancer drug trial results shares of mei pharma meip plunged to a oneyear low on monday after the company announced its cancer drug pracinostat failed to meet its main goal in a midstage trial mar    am edt first week of april th options trading for mei pharma meip investors in mei pharma inc saw new options become available this week for the april th expiration at stock options channel our yieldboost formula has looked up and down the meip options chain for the new april th contracts and identified one put and one call contract of particular interest feb    am est  biotech stocks under  triggering breakouts amarin exelixis and more keep these under biotech stocks on your breakout trading radar feb    pm est  under health care stocks setting up to trade higher these setups often produce monster moves higher in very short time frames jan    am est oversold conditions for mei pharma meip legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful one way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the relative strength index or rsi which measures momentum on a scale of zero to  nov    pm est  under health care stocks triggering breakout trades keep these health care stocks under  on your breakout trading radar oct    am edt  breakout stocks under  set to soar these under stocks look ready to break out and trade higher from current levels sep    pm edt  biotech stocks under  to trade for breakouts these under biotech stocks are within range of triggering breakout trades jul    am edt  biotech stocks under  to watch for breakout trades these under biotech stocks are within range of triggering breakout trades jul    am edt  stocks under  set to soar these under stocks are within range of triggering breakout trades may    pm edt relative strength alert for mei pharma legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful one way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the relative strength index or rsi which measures momentum on a scale of zero to  may    pm edt  stocks spiking on big volume unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst mar    am edt  stocks under  triggering breakouts these under stocks are within range of triggering breakout trades mar    am est  stocks ready to break out these stocks look ready to break out and trade higher from current levels jan    pm est  biotech stocks under  making big moves keep these under biotech stocks on your radar jan    am est  stocks under  to trade for breakouts these under stocks are within range of triggering breakout trades dec    am est mei pharma is now oversold meip legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful one way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the relative strength index or rsi which measures momentum on a scale of zero to  nov    pm est taking cues from the insiders against this difficult backdrop insider activity can serve as a useful guide for our next move oct    am edt mei pharma enters oversold territory meip legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful one way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the relative strength index or rsi which measures momentum on a scale of zero to  jun    pm edt  stocks under  trending sharply higher regardless of the reason behind it when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits may    pm edt next load more quant rating on  pm edt  d sell get the meip report here from our partners mei pharma double trouble or double double seekingalpha healthcare  top  gainers  losers as of  am seekingalpha mei pharma meip worth a look stock rises  in session zacks concordia international cxrx catches eye stock jumps  zacks healthcare  top  gainers  losers as of  am seekingalpha why i invest in microcaps seekingalpha mei pharmas blood cancer candidate me performs well in earlystage study shares up  seekingalpha premarket gainers as of  am seekingalpha mei pharma meip shows strength stock moves  higher zacks mei pharma initiated with an outperform at oppenheimer the fly calithera biosciences cala jumps stock moves  higher zacks mei pharma beats by  misses on revenue seekingalpha first quarter  letter conscious capitalists seekingalpha mei pharma meip presents at th annual needham healthcare conference  slideshow seekingalpha new finance chief at mei pharma seekingalpha thestreet quant rating d sell get the meip report here trending walmart in focus amid horrific human trafficking incident in texas that causes nine deaths trump just resurrected the ugly practice known as civil forfeiture for no reason billionaire mark cuban the rise of technology will cause a lot of unemployment as snap continues to stumble should it consider selling itself chipotle is doomed unless it takes this one dramatic measure advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers about us  mei pharma skip to main content search form search print email about us mei pharma is a san diegobased oncology company focused on the clinical development of novel therapies for cancer our portfolio of drug candidates includes pracinostat an oral hdac inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia aml and myelodysplastic syndrome mds our clinical development pipeline also includes me a highly selective oral pik delta inhibitor and me a novel mitochondrial inhibitor in august  we announced that the us food  drug administration granted breakthrough therapy designation for pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed aml who are unfit for intensive chemotherapy later that month we entered into an exclusive licensing development and commercialization agreement with helsinn healthcare sa a swiss pharmaceutical company for pracinostat in aml and other potential indications including mds me is a potent and selective oral inhibitor of pik delta a molecular target that plays a critical role in the proliferation and survival of certain hematologic cancer cells results from a firstinhuman single ascending dose clinical study suggest that me has the potential for an improved therapeutic window compared to other pik delta inhibitors with a halflife that supports oncedaily dosing a phase ib doseescalation study of me in patients with relapsedrefractory chronic lymphocytic leukemia cll or follicular lymphoma opened for enrollment in september  me is our isoflavonederived mitochondrial inhibitor drug candidate results from a phase i clinical study of me in patients with refractory solid tumors showed evidence of clinical activity including a confirmed partial response in a heavily pretreated patient with small cell lung cancer who remained on study for two years an investigatorsponsored study of me in combination with the vegf inhibitor bevacizumab marketed as avastin® in hernegative breast cancer opened for enrollment in august  mei pharma is listed on the nasdaq capital market nasdaq meip   management our management team comes with a deep understanding of oncology drug development including experience with the worlds leading oncology drugsread more directors our board of directors combines decades of oncology drug development business and wall street experience to add valuable perspective to the companyread more search form search print email home about usmanagement directors programs newsroom investors careers contact mei pharma  pioneering new therapies for cancer skip to main content search form search print email pioneering new therapies for cancer   about us we are a san diegobased oncology company focused on the clinical development of novel therapies for cancer our pipeline of drug candidates includes pracinostat an oral hdac inhibitor in latestage clinical development for the treatment of aml and mds me a highly selective pik delta inhibitor being developed for bcell malignancies and me a novel mitochondrial inhibitorread about us latest news correlation between gene mutations and clinical response in phase ii study of pracinostat and azacitidine in amlpress release  asco  eha first patient dosed in phase  doseoptimization study of pracinostat and azacitidine in mdspress release prespecified response rate exceeded in doseescalation study of me in cll and follicular lymphomapress release third quarter fiscal year  resultspress release  q presentation at needham healthcare conferencewebcast  slides   highlights view  annual review mei pharma appoints new cfo mei pharma rides wave of interest in aml search form search print email home about us programs newsroom investors careers contact bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one